Charles River Laboratories International Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Charles River Laboratories International Stock Forecast and Price Target
According to eleven experts, who recently provided their 2024 price targets for Charles River Laboratories International, the average price target is $276.75, with a high estimate of $300.00 and a low estimate of $235.00. That is a potential upside of approximately 21.62% from the last closing price of $227.55 on April, 2024. If you want to buy CRL stock, it might be a good idea to look at its competitors too.
21.62% Upside
Charles River Laboratories International Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Charles River Laboratories International's Price has decreased by 100.00%, from $198.53 to $0.00. In the next year, analysts predict that Fair Value will reach $273.50 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.23 | Buy/Sell | $130.51 | 11.00% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$541.52 | Buy/Sell | $591.94 | 12.00% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF84.52 | Buy/Sell | CHF105.00 | 24.59% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$233.15 | Buy/Sell | $284.47 | 20.09% |
| MMM Stock Forecast | 3M | Hold |
10
|
$91.48 | Buy/Sell | $109.39 | 9.31% |
Charles River Laboratories International Revenue Forecast for 2023 - 2025 - 2030
Charles River Laboratories International's Revenue has grown in the last three years, jumping from $2.92B to $4.13B – an increase of 41.23%. In the next year, analysts predict that Revenue will reach $4.29B – an increase of 3.99%. For the next nine years, the forecast is for Revenue to grow by 70.39%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IQV Stock Forecast | IQVIA Holdings | Outperform |
15
|
$227.17 | Buy/Sell | $267.27 | 21.05% |
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF510.20 | Buy/Sell | CHF516.89 | 14.66% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.09k | Buy/Sell | ¥4.74k | 13.72% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DAL Stock Forecast | Delta Air Lines | Buy |
15
|
$47.85 | Buy/Sell | $52.89 | 19.12% |
| RYA Stock Forecast | Ryanair Holdings | Buy |
9
|
20.55€ | Buy/Sell | 23.71€ | 26.52% |
| ICLR Stock Forecast | ICON Public | Buy |
16
|
$291.82 | Buy/Sell | $306.07 | 22.51% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4901 Stock Forecast | FUJIFILM Holdings | Buy |
18
|
¥9.41k | Buy/Sell | ¥10.57k | 9.43% |
| LUV Stock Forecast | Southwest Airlines | Hold |
12
|
$29.06 | Buy/Sell | $27.53 | -0.72% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$199.45 | Buy/Sell | $241.28 | 20.33% |
Charles River Laboratories International EBITDA Forecast for 2023 - 2025 - 2030
Charles River Laboratories International's EBITDA has increased by 40.48% In the last three years, going from $690.68M to $970.29M. In the next year, analysts expect EBITDA to reach $1.07B – an increase of 10.36%. For the next nine years, the forecast is for EBITDA to grow by 28.28%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 603259 Stock Forecast | WuXi AppTec | Buy |
18
|
¥43.43 | Buy/Sell | ¥121.48 | 54.89% |
| SGSN Stock Forecast | SGS | Hold |
18
|
CHF82.00 | Buy/Sell | CHF86.34 | 9.76% |
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$125.91 | Buy/Sell | $141.17 | 13.02% |
Charles River Laboratories International EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Charles River Laboratories International's EBIT has grown, increasing from $455.76M to $656.17M – a growth of 43.97%. The next year looks promising for Charles River Laboratories International, with analysts predicting EBIT of $881.45M – an increase of 34.33%. Over the next eleven years, experts anticipate that Charles River Laboratories International's EBIT will grow at a rate of 96.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 753 Stock Forecast | Air China | Outperform |
7
|
HK$3.83 | Buy/Sell | HK$6.09 | 40.73% |
| BVI Stock Forecast | Bureau Veritas | Outperform |
18
|
27.20€ | Buy/Sell | 26.96€ | 12.13% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
99.00€ | Buy/Sell | 105.55€ | 13.13% |
Charles River Laboratories International EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Charles River Laboratories International's EPS has decreased by 100.00%, from $8.13 to $0.00. In the next year, analysts predict that EPS will reach $11.20 – an increase of 100.00%. For the next nine years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| THYAO Stock Forecast | Türk Hava Yollari Anonim Orta... | Buy |
10
|
₺296.25 | Buy/Sell | ₺324.44 | 29.96% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
60.08€ | Buy/Sell | 0.00€ | -1.80% |
| 1055 Stock Forecast | China Southern Airlines Compan... | Outperform |
10
|
HK$2.68 | Buy/Sell | HK$4.38 | 25.37% |
Site Navigation
.jpg)